SPONSORSHIP ALLIANCE NEWS
In collaboration with the Cureus Journal of Medicine (Springer Nature), ZAP is proud to sponsor the Dedicated Cranial Radiosurgery: Clinical Experience with New & Innovative SRS Technologies publishing competition. Looking at novel SRS-exclusive delivery platforms, the program seeks case reports, case series and/or technical reports. All resulting publications will be indexed with Pub-Med Central.
$9,000 USD in honoraria awarded via crowd-sourced scoring across the top 3 article authors.
Deadline for draft article submission is April 22, 2025. For more details, please visit https://www.cureus.com/competitions/CranialSRS.
The next-generation Radiosurgery Planning System (RPS) specifically engineered to harness the full potential of the ZAP-X® Gyroscopic Radiosurgery® platform*. Axon delivers unmatched simplicity, remarkable speed, and clinical excellence, setting a new benchmark in cranial SRS treatment planning.
* Pending USA FDA and EU CE clearance
Learn more about the new ZAP-Axon Radiosurgery Planning System here.
AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence and no epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. In this regimen, patients are treated with Imfinzi in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery.
RefleXion announced the initiation of the BIOGUIDE-X2 clinical study to expand indications for SCINTIX biology-guided radiotherapy. Additionally, the Centers for Medicare and Medicaid (CMS) has expanded reimbursement for SCINTIX therapy to include freestanding cancer centers (FSC), and created a modifier to allow for professional reimbursement for physicians in both FSC and hospital outpatient departments.
On behalf of the Cureus Journal of Medicine (Springer Nature), ZAP is proud to sponsor the Dedicated Cranial Radiosurgery: Clinical Experience with New & Innovative SRS Technologies publishing competition. Looking at novel SRS-exclusive delivery platforms, the program seeks case reports, case series and/or technical reports. All resulting publications will be indexed with Pub-Med Central.
It's a great opportunity to showcase your expertise in state-of-the-art radiosurgery, and educate your peers on new and innovative technologies. And there are $9,000 USD in honoraria to be awarded via crowd-sourced scoring across the top 3 article authors.
For more details, please visit https://www.cureus.com/competitions/CranialSRS. Deadline for draft article submission is April 22, 2025.
Congratulations to Dr. John Adler on his induction into the National Inventors Hall of Fame as part of the class of 2025!
The National Inventors Hall of Fame® celebrates groundbreaking inventors, inspires creativity, and promotes the values of innovation and entrepreneurship.
Discover the full class of 2025 here: https://www.invent.org/inductees/new-inductees
We invite you to submit your radiation therapy case studies that demonstrate the impact and potential of Synchrony® real-time adaptive motion management in any body site. Whether you are working on a Radixact® System or a CyberKnife® System, your insights and findings are invaluable to the medical community.
To participate, please visit the competition page for submission guidelines. The deadline for submissions is Wednesday, March 12th, 2025 and winners will be announced in May 2025. We look forward to your contributions and to celebrating these advancements in radiation therapy together.
Join your fellow Leksell Gamma Knife practitioners for an exclusive opportunity to explore the latest advancements and innovations in Gamma Knife radiosurgery. The call for abstracts for the Leksell Gamma Knife Society Meeting is now open.
The theme for the Leksell Gamma Knife Society Meeting – Stockholm 2025 is ‘Continue to Lead’. We believe it is crucial we all learn from our findings, our challenges and our best practices to pave the way for the future. So, we encourage you to share your most significant findings and submit an abstract. Learn more here: https://tinyurl.com/ycy5j66s
Datopotamab deruxtecan (Dato-DXd) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) with disease progression on or after treatment with an EGFR-tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy.
AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
Investment Aims to Further Accelerate Manufacturing, Sales, and Distribution of the ZAP-X Gyroscopic Radiosurgery Platform
ZAP-X demonstrated potent anti-tumor efficacy and adequate tolerability and should be considered a new treatment option for relapsed refractory patients.
As the sponsor of the meeting, Vision RT announces that abstracts are open for the 2025 US SGRT Community Meeting, being held at the Grand Hyatt Hotel in downtown Denver, CO on June 4-6, 2025. This will be an opportunity to share best practices and network with peers in a venue surrounded by the majesty of the Rocky Mountains. We invite you to submit on any surface guidance topic through the Simulation, Planning, Treatment and Dose Visualization steps. Travel grants are available for successful submissions, and the abstract window will close on Monday, February 3, 2025. Attendance to this event will be completely FREE and 100% peer-driven, with all sessions and talks delivered by SGRT users. The three-day event will be made up of an on-site visit to an SGRT expert user center, presentations, workshops, and the latest innovations, as well as real-life case reports.
